Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.83
OPK's Cash to Debt is ranked higher than
54% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. OPK: 0.83 )
OPK' s 10-Year Cash to Debt Range
Min: 0.48   Max: No Debt
Current: 0.83

Equity to Asset 0.63
OPK's Equity to Asset is ranked higher than
66% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. OPK: 0.63 )
OPK' s 10-Year Equity to Asset Range
Min: 0.02   Max: 0.96
Current: 0.63

0.02
0.96
F-Score: 4
Z-Score: 3.33
M-Score: -2.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -82.49
OPK's Operating margin (%) is ranked lower than
54% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 6.75 vs. OPK: -82.49 )
OPK' s 10-Year Operating margin (%) Range
Min: -31624.44   Max: -39.08
Current: -82.49

-31624.44
-39.08
Net-margin (%) -118.52
OPK's Net-margin (%) is ranked lower than
55% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.06 vs. OPK: -118.52 )
OPK' s 10-Year Net-margin (%) Range
Min: -44561.54   Max: -4.59
Current: -118.52

-44561.54
-4.59
ROE (%) -13.05
OPK's ROE (%) is ranked higher than
53% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. OPK: -13.05 )
OPK' s 10-Year ROE (%) Range
Min: -11095.82   Max: -0.8
Current: -13.05

-11095.82
-0.8
ROA (%) -8.22
OPK's ROA (%) is ranked higher than
54% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. OPK: -8.22 )
OPK' s 10-Year ROA (%) Range
Min: -678.34   Max: -0.56
Current: -8.22

-678.34
-0.56
ROC (Joel Greenblatt) (%) -467.68
OPK's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 12.75 vs. OPK: -467.68 )
OPK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -68366.67   Max: -43.04
Current: -467.68

-68366.67
-43.04
Revenue Growth (%) 34.90
OPK's Revenue Growth (%) is ranked higher than
97% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. OPK: 34.90 )
OPK' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 135.1
Current: 34.9

0
135.1
EBITDA Growth (%) 91.30
OPK's EBITDA Growth (%) is ranked higher than
99% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. OPK: 91.30 )
OPK' s 10-Year EBITDA Growth (%) Range
Min: -75.7   Max: 171.4
Current: 91.3

-75.7
171.4
EPS Growth (%) 74.70
OPK's EPS Growth (%) is ranked higher than
98% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. OPK: 74.70 )
OPK' s 10-Year EPS Growth (%) Range
Min: -69.4   Max: 152.4
Current: 74.7

-69.4
152.4
» OPK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

OPK Guru Trades in Q1 2013

Murray Stahl 40,761 sh (+0.69%)
Mario Gabelli 15,000 sh (unchged)
Steven Cohen Sold Out
» More
Q2 2013

OPK Guru Trades in Q2 2013

Murray Stahl 44,698 sh (+9.66%)
Mario Gabelli 15,000 sh (unchged)
» More
Q3 2013

OPK Guru Trades in Q3 2013

Jim Simons 17,802 sh (New)
George Soros 745,000 sh (New)
Steven Cohen 29,200 sh (New)
Murray Stahl 79,305 sh (+77.42%)
Mario Gabelli 15,000 sh (unchged)
» More
Q4 2013

OPK Guru Trades in Q4 2013

Steven Cohen 46,194 sh (+58.2%)
Murray Stahl 97,806 sh (+23.33%)
George Soros 844,600 sh (+13.37%)
Mario Gabelli 15,000 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OPK

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-09-30 New Buy0.07%$7.18 - $9.24 $ 8.142%745000
Mario Gabelli 2011-03-31 Reduce -90.58%$3.48 - $4.83 $ 8.14103%15000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Opko Health, Inc.

Weekly CEO Buys Highlight: OPK, AMRC, CLMS, OILT, WMC
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, RTRX, TFM, CSBK, AHP
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: KCG, OPK, HOLX, CLMS, TDC
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, GE, CLMS, HELI, GAM
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, HELI, RSPP, CLMS
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Largest CEO Buys Over the Past Week
There were several notable CEO buys occurring over the past week.  These buys have proven to be exceptionally notable because these upper corporate executives are expected to have the most knowledge about the inner workings of their company.  The following buys have all been reported by corporation’s CEOs and hold the highest transaction amount according to GuruFocus CEO Buys. Read more...
Weekly CEO Buys Highlight: OPK, CLMS
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/B 3.84
OPK's P/B is ranked higher than
51% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. OPK: 3.84 )
OPK' s 10-Year P/B Range
Min: 3.65   Max: 50.6
Current: 3.84

3.65
50.6
P/S 29.07
OPK's P/S is ranked lower than
85% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. OPK: 29.07 )
OPK' s 10-Year P/S Range
Min: 15.25   Max: 126.5
Current: 29.07

15.25
126.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 8.06
OPK's Price/DCF (Projected) is ranked lower than
72% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. OPK: 8.06 )
OPK' s 10-Year Price/DCF (Projected) Range
Min: 8.36   Max: 8.36
Current: 8.06

Price/Median PS Value 0.90
OPK's Price/Median PS Value is ranked higher than
80% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. OPK: 0.90 )
OPK' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 5.59
Current: 0.9

0.28
5.59
Forward Rate of Return (Yacktman) 4.77
OPK's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. OPK: 4.77 )
OPK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.8   Max: 45.9
Current: 4.77

1.8
45.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XCY.Germany
Opko Health, Inc. was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc., which was later changed to eXegenics, Inc. On June 8, 2007, the Company changed its name to OPKO Health, Inc. It is a biopharmaceutical and diagnostics company, which is focused on the discovery, development, and commercialization of proprietary pharmaceuticals, diagnostic and imaging systems and instrumentation products for the treatment, diagnosis and management of ophthalmic diseases and conditions. The Company's business presently consists of the development of ophthalmic pharmaceuticals and the development, commercialization and sale of ophthalmic diagnostic and imaging systems and instrumentation products. The Company operates a U.S.-based laboratory certified under the Clinical Laboratory Improvement Amendments of 1988, as amended ("CLIA"), with a urologic focus that it expects will serve as a commercial platform for the U.S. launch of OPKO's next generation test for the early detection of prostate cancer. In addition, it operates a specialty active pharmaceutical ingredients ("APIs") manufacturer in Israel, which it expects will play a valuable role in the development of its pipeline of molecules and compounds for their proprietary molecular diagnostic and therapeutic products. It continues to actively explore opportunities to acquire complementary pharmaceuticals, compounds, technologies, and businesses. In late 2011, it acquired a novel diagnostic instrument system that provides rapid, high performance blood test results and enables complex tests to be run in point-of-care settings. The Company faces competition from competitors for its instrumentation products located in the United States and abroad, which competitors include companies with a far more diverse product offering and greater market presence than its, such as Carl Zeiss Meditec, Topcon Corporation, and Heidelberg Engineering, as well as a number of smaller competitors and smaller start-up companies that might also have competing technologies and products. The Company is also subject to various federal, state, and international laws pertaining to health care 'fraud and abuse,' including anti-kickback laws and false claims laws.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide